| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return | vs S&P 500 ⓘ |
|---|---|---|---|---|---|---|
|
TARA
Protara Therapeutics
|
Aug 12, 2026 | BUY |
Strong Buy
+1223.0% avg upside
21 analysts
|
$27.00
597.76% Upside
|
+1.4% | · |
|
ENGN
enGene Holdings
|
Aug 12, 2026 | BUY |
Buy
+481.4% avg upside
13 analysts
|
$4.00
127.94% Upside
|
+1.2% | · |
|
AURA
Aura Biosciences Inc
|
Aug 12, 2026 | BUY |
Strong Buy
+164.0% avg upside
9 analysts
|
$18.00
145.95% Upside
|
+0.0% | · |
|
ERAS
Erasca
|
Aug 12, 2026 | BUY |
Strong Buy
+9.7% avg upside
14 analysts
|
$22.00
15.96% Upside
|
-2.9% | · |
|
TCRX
TScan Therapeutics
|
Aug 12, 2026 | BUY |
Strong Buy
+1003.4% avg upside
12 analysts
|
$7.00
827.19% Upside
|
+0.0% | · |
|
IMNM
Immunome
|
Aug 12, 2026 | BUY |
Strong Buy
+23.6% avg upside
16 analysts
|
$40.00
47.57% Upside
|
-1.9% | · |
|
SRRK
Scholar Rock Holding
|
Aug 10, 2026 | BUY |
Strong Buy
+6.6% avg upside
23 analysts
|
$65.00
19.97% Upside
|
+5.8% | · |
|
RLMD
Relmada Therapeutics
|
Aug 10, 2026 | BUY |
Buy
+193.5% avg upside
15 analysts
|
$12.00
155.33% Upside
|
+6.6% | · |
|
CRBP
Corbus Pharmaceuticals
|
Aug 07, 2026 | BUY |
Strong Buy
+270.1% avg upside
20 analysts
|
$35.00
268.46% Upside
|
-1.5% | · |
|
VSTM
Verastem
|
Aug 07, 2026 | BUY |
Strong Buy
+118.8% avg upside
24 analysts
|
$18.00
157.80% Upside
|
+0.3% | · |
|
ZNTL
Zentalis Pharmaceuticals
|
Aug 07, 2026 | BUY |
Buy
+228.4% avg upside
18 analysts
|
$10.00
140.98% Upside
|
-1.7% | · |
|
FHTX
Foghorn Therapeutics
|
Aug 07, 2026 | BUY |
Strong Buy
+79.9% avg upside
17 analysts
|
$13.00
98.16% Upside
|
+7.7% | · |
|
CGON
CG Oncology, Inc.
|
Aug 07, 2026 | BUY |
Strong Buy
+11.6% avg upside
17 analysts
|
$100.00
28.66% Upside
|
+1.8% | · |
|
IMRX
Immuneering
|
Aug 06, 2026 | BUY |
Strong Buy
+260.5% avg upside
12 analysts
|
$14.00
184.55% Upside
|
+1.6% | · |
|
SNDX
Syndax Pharmaceuticals
|
Aug 05, 2026 | BUY |
Strong Buy
+75.4% avg upside
27 analysts
|
$38.00
85.67% Upside
|
-1.8% | · |
|
KROS
Keros Therapeutics
|
Aug 04, 2026 | BUY |
Strong Buy
+119.7% avg upside
21 analysts
|
$20.00
87.50% Upside
|
+9.3% | · |
|
IBRX
ImmunityBio
|
Aug 04, 2026 | BUY |
Strong Buy
+46.1% avg upside
12 analysts
|
$15.00
95.84% Upside
|
+9.9% | · |
|
CADL
Candel Therapeutics
|
Jul 29, 2026 | BUY |
Strong Buy
+70.2% avg upside
11 analysts
|
$23.00
114.72% Upside
|
+19.3% | · |
|
MNPR
Monopar Therapeutics Inc
|
Jul 22, 2026 | BUY |
Strong Buy
-10.7% avg upside
18 analysts
|
$125.00
9.74% Upside
|
-2.3% | · |
|
NBP
NovaBridge Biosciences
|
May 26, 2026 | BUY |
Strong Buy
+1046.9% avg upside
14 analysts
|
$9.00
386.49% Upside
|
-5.9% | · |
|
STRO
Sutro Biopharma
|
May 26, 2026 | BUY |
Strong Buy
+88.8% avg upside
21 analysts
|
$50.00
156.23% Upside
|
-6.8% | · |
|
HOWL
Werewolf Therapeutics
|
Dec 19, 2025 | BUY |
Strong Buy
+1706.1% avg upside
8 analysts
|
$4.00
955.46% Upside
|
-43.5% | · |
|
IMA
ImageneBio
|
Nov 11, 2024 | BUY |
Buy
+187.2% avg upside
12 analysts
|
$4.00
30.40% Downside
|
-59.0% | · |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.